CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
STA-9090drug
Likely dose
STA-9090 200 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01273896
NCT01273896Phase 2Completed
CompareCT.gov

A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 11, 2011·Updated Nov 20, 2015

In Brief

A Phase 2 clinical trial evaluating STA-9090 for Breast Cancer. Completed, enrolled 22 participants across 5 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, STA-9090 has on the patient and their breast cancer. STA-9090 is an experimental drug that works by breaking down cancer proteins. When the cancer proteins are destroyed, the cancer cells die. STA-9090 is an experimental drug that is not yet approved for the treatment of cancer by the United States (FDA) Food and Drug Administration . STA-9090 has been tested in cancer patients in other trials and a safe dose for this drug has been found. We are now interested to see how active this drug is against breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsSynta Pharmaceuticals Corp.

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2011
Enrollment StartJan 1, 2011
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.5 years ago

Interventions

STA-9090drug

All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.